公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2024 | Ten-year epidemiology and risk factors of cytomegalovirus infection in hematopoietic stem cell transplantation patients in Taiwan | Huang, Yi-Che; Hsiao, Fei-Yuan; Guan, Shang-Ting; MING YAO ; Liu, Chia-Jen; Chen, Tzu-Ting; Lin, Tung-Liang; Liu, Yi-Chang; Chen, Tsai-Yun; Hong, Ying-Chung; Ma, Ming-Chun; Tan, Tran-Der; Wang, Chuan-Cheng; Wu, Yi-Ying; Liao, Po-Wei; Wu, Yi-Feng; Chen, Yi-Yang; Yu, Yuan-Bin; Hsieh, Yao-Yu; Lee, Ming-Yang; Liu, Jia-Hau; Lin, Shu-Wen; BOR-SHENG KO | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi | | | |
2011 | TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics | WEN-CHIEN CHOU ; SHENG-CHIEH CHOU ; Liu C.-Y.; Chen, Chien-Yuan ; HSIN-AN HOU ; Kuo Y.-Y.; Lee M.-C.; BOR-SHENG KO ; JIH-LUH TANG ; MING YAO ; WOEI TSAY ; SHANG-JU WU ; SHANG-YI HUANG ; SZU-CHUN HSU ; YAO-CHANG CHEN ; Chang Y.-C.; Kuo Y.-Y.; KUAN-TING KUO ; Lee F.-Y.; Liu M.-C.; Liu C.-W.; Tseng M.-H.; Huang C.-F.; HWEI-FANG TIEN | Blood | 255 | 235 | |
2015 | TP53 mutations in de novo acute myeloid leukemia patients: Longitudinal follow-ups show the mutation is stable during disease evolution | HSIN-AN HOU ; WEN-CHIEN CHOU ; Kuo, Y.-Y.; Liu, C.-Y.; LIANG-IN LIN ; Tseng, M.-H.; Chiang, Y.-C.; Liu, M.-C.; Liu, C.-W.; JIH-LUH TANG ; MING YAO ; Li, C.-C.; SHANG-YI HUANG ; BOR-SHENG KO ; SZU-CHUN HSU ; Chen, Chien-Yuan ; Lin, C.-T.; SHANG-JU WU ; WOEI TSAY ; YAO-CHANG CHEN ; HWEI-FANG TIEN | Blood Cancer Journal | 112 | 111 | |
2021 | Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study | Chen, Mei-Tsen; Huang, Shih-Tsung; Lin, Chih-Wan; BOR-SHENG KO ; WEN-JONE CHEN ; HUAI-HSUAN HUANG ; FEI-YUAN HSIAO | The oncologist | 7 | 5 | |
2013 | Upregulation of Focal adhesion kinase by 14-3-3ε via NFκB activation in Hepatocellular Carcinoma | BOR-SHENG KO ; Jan Y.-J.; Chang T.-C.; Liang S.-M.; Chen S.-C.; Liu T.-A.; YAO-MING WU ; Wang J.; Liou J.-Y. | Anti-Cancer Agents in Medicinal Chemistry | 28 | 23 | |
2023 | Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myeloid leukemia | Lo, Min-Yen; Tsai, Xavier Cheng-Hong; CHIEN-CHIN LIN ; FENG-MING TIEN ; Kuo, Yuan-Yeh; WAN-HSUAN LEE ; Peng, Yen-Ling; Liu, Ming-Chih; Tseng, Mei-Hsuan; Hsu, Cheng-An; JUI-CHE CHEN ; LIANG-IN LIN ; Sun, Hsun-I; Chuang, Yi-Kuang; BOR-SHENG KO ; JIH-LUH TANG ; MING YAO ; WEN-CHIEN CHOU ; HSIN-AN HOU ; HWEI-FANG TIEN | American journal of hematology | 4 | 4 | |
2019 | Women with diffuse large B cell lymphoma benefit more from rituximab-containing chemotherapy | HUAI-HSUAN HUANG ; FEI-YUAN HSIAO ; Chen L.-J.; Chen H.-M.; BOR-SHENG KO | Journal of Women's Health | 5 | 6 | |
2010 | WT1 mutation in 470 adult patients with acute myeloid leukemia: Stability during disease evolution and implication of its incorporation into a survival scoring system | HSIN-AN HOU ; TAI-CHUNG HUANG ; LIANG-IN LIN ; Liu C.-Y.; Chen, Chien-Yuan ; WEN-CHIEN CHOU ; JIH-LUH TANG ; Tseng M.-H.; Huang C.-F.; Chiang Y.-C.; Lee F.-Y.; Liu M.-C.; MING YAO ; SHANG-YI HUANG ; BOR-SHENG KO ; SZU-CHUN HSU ; SHANG-JU WU ; WOEI TSAY ; YAO-CHANG CHEN ; HWEI-FANG TIEN | Blood | 142 | 137 | |
2019 | ZNF479 downregulates metallothionein-1 expression by regulating ASH2L and DNMT1 in hepatocellular carcinoma | Wu Y.-J.; BOR-SHENG KO ; Liang S.-M.; Lu Y.-J.; Jan Y.-J.; Jiang S.-S.; Shyue S.-K.; Chen L.; Liou J.-Y. | Cell Death and Disease | 16 | 14 | |